Building a diversified sustainable healthcare portfolio
Investing in healthcare is complex. You must get into the weeds of the molecular R&D environment, understand a range of differing competitive and regulatory terrains, and understand just how hard it is to develop software and hardware in medical devices and digital therapies. All this without taking into account the rapidly changing, post-pandemic landscape.
But, at the same time, on another level, it is simple: pharma, makers of medical devices, diagnostics developers and digital health developers must offer value to all stakeholders – to patients, healthcare providers and payers.
Value is the big, overarching theme in sustainable healthcare investment for Dr Michael Schröter and Dr Nathalie Flury, co-heads at the Global Equity Sustainable Healthcare Fund. And it is clear that much value is to be found beyond classic biotech. “Delivering care and reducing cost can also be achieved with medical devices and digital applications, and through service and diagnostics,” says Schröter. "We are investing in all these subsectors. We also see more interplay between these subsectors.”
While biotech has the largest weighting within the fund – around 38 per cent1 – Flury and Schröter are clear about the need to limit this and to achieve diversity over the five investment sub-segments they have identified. “I have managed pure biotech portfolios in the past, and it is a volatile segment,” says Flury. “If things don’t work for developing or approving a product, it can mean minus 60 to 70 per cent for a stock; our investment philosophy allows us to find companies in many segments of healthcare.”
Doubling down in digital
The flexible approach paid off for the fund early in 2020, as the scale of disruption owing to the pandemic became clear, along with the merits of remote care. The Sustainable Healthcare Fund was agile enough to double down, extending its weighting to 25 per cent in digital and telehealth investments in response to the pandemic, says Flury. “We were 5 per cent invested in digital health solutions in January 2020, mainly in Teladoc Health and Ping An. By March, we realised the pandemic was not going to be over quickly. We saw the pressure the system would be under, as well as the increasing acceptance of these approaches by patients and doctors, and we realised we had to increase our position in digital healthcare stocks.”
Even now, the wider digital health sector holds further promise to help us all understand and manage our health better in future. However, for investors, it is also frothy and replete with risk. Choosing where to find value among many thousands of health and wellness apps, during such a fervid phase of ever pricier venture capital deals, discernment and specialist knowledge are all. “From an investment standpoint, you need to watch out. There are plenty of companies in the digital space. There are 600,000 health apps, for example, but you can count on one hand those which are profitable,” says Schröter.
Without an understanding of the sector’s complexity, an over-confident, technology-first approach to innovation in the sector is unlikely to end well. It is a lesson the tech giants such as Google and Amazon, which are eyeing the opportunities in health, have experienced first-hand, he adds. "It’s not a technical problem you are typically solving. Usually it is about integrating a solution into a complex healthcare environment."
For those who understand the interlocking complexities of care delivery pathways and reimbursement processes, there is great scope to back the right kinds of digital healthcare innovation. Companies that focus on big data to help identify optimal treatments, or appropriate care follow-ups, for example, identifying at-risk patient cohorts that can be engaged earlier to head off disease progression, offer one interesting digital healthcare investment theme with great cost-saving potential.
Another theme in this area is in deploying monitoring technology to patients. One US healthcare provider uses phones to detect postpartum depression, enabling it to take preventative measures. Digital therapeutics that help patients understand and adapt their behaviour and approach to their disease are also showing great promise in areas including metabolic and mental health.
Backing the mid market
In conventional pharma, when assessing a prospective biopharma investment, Flury and Schröter look for a range of features beyond the usual due diligence around financial and regulatory risks. Products must have clear competitive advantages over existing ones, including not only efficacy but also how they can help improve overall standards of care, as well as value to providers and payers. “Is this product better than what’s on the market? And we prefer companies with more than one product because, with single product companies, the full value is in one place and, if it doesn’t work in phase 3, the risk is very high,” says Flury.
Another important feature of the fund’s approach is its mid-cap bias (investments valued at between $500 million and $20 billion) across all subsectors, says Schröter. Much of its investment is focused on the US, but, he says: “This is only a reflection of where the bulk of innovation is happening today. That will change over time. Our Asian exposure will change as more innovation comes out of the region.”
- Capital loss risk: It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed
- Equity risk: Funds that invest in securities listed on a stock exchange or market could be affected by general changes in the stock market. The value of investments can go down as well as up due to equity markets movements
- Discretionary management risk: Discretionary management is based on anticipating the evolution of different markets and securities. There is a risk that the fund will not be invested at any time in the most efficient markets and securities
- Foreign Exchange risk: Where overseas investments are held, the rate of exchange of the currency may cause the value to go down as well as up. Variations in exchange rates between currencies can have a significant impact on the performance of the products presented
- Small & Mid cap risk: Please note that the fund is invested in securities issued by companies which, due to their small or mid-market capitalization, are less liquid and may present higher risks
This document is only intended for professional investors as defined by MIFID, in Switzerland by HSBC Global Asset Management (Switzerland) AG and is only intended for qualified investors in the meaning of Art. 10 para 3 of the Federal Collective Investment Schemes Act (CISA). All non-authorised reproduction or use of this commentary and analysis will be the responsibility of the user and will be likely to lead to legal proceedings. This document has no contractual value and is not by any means intended as a solicitation, nor an investment advice for the purchase or sale of any financial instrument in any jurisdiction in which such an offer is not lawful. The commentary and analysis presented in this document reflect the opinion of HSBC Asset Management on the markets, according to the information available to date. They do not constitute any kind of commitment from HSBC Global Asset Management (France). Consequently, HSBC Asset Management will not be held responsible for any investment or disinvestment decision taken on the basis of the commentary and/or analysis in this document.
If necessary, investors can refer to the complaints handling charter available in the banner of our website.
Please note that the distribution of the product can stop at any time by decision of the management company.
Tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Capital is not guaranteed. It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed.
Past performance is no guarantee of future returns. Future returns will depend inter alia on market developments, the fund manager’s skill, the fund’s level risk and management costs and if applicable subscription and redemption costs. The return, the value of money invested in the fund may become negative as a result of price losses and currency fluctuations. There is no guarantee that all of your invested capital can be redeemed. Unless stated otherwise, inflation is not taken into account.
Synthetic Risk and Reward Indicator (SRRI): 6 out of 7. Do not run any unnecessary risk. Read the Key Investor Information Document. The fund invests in instruments of high level of volatility. The value of investments can go up as well as down. The rating is based on price volatility over the last five years, and is an indicator of absolute risk. Historical data may not be a reliable indication for the future. The scale varies from 1 (least risky) to 7 (most risky). The rating is not guaranteed to remain unchanged and the categorisation may shift over time. The lowest rating does not mean a risk-free investment. Do not run any unnecessary risk. Read the Key Investor Information Document.
Important information for Luxembourg investors: HSBC entities in Luxembourg are regulated and authorised by the Commission de Surveillance du Secteur Financier (CSSF).
Important information for Swiss investors: This document may be distributed in Switzerland only to qualified investors according to Art. 10 para 3, 3bis and 3ter CISA. The presented fund is authorised for distribution in Switzerland in the meaning of Art. 120 CISA. (Potential) investors are kindly asked to consult the latest issued Key Investor Information Document (KIID), prospectus, articles of incorporation and the (semi-)annual report of the fund which may be obtained free of charge at the head office of the representative: HSBC Global Asset Management (Switzerland) AG, Gartenstrasse26, P.O. Box, CH-8002 Zurich. Paying agent in Switzerland: HSBC Private Bank (Suisse) SA, Quai des Bergues9-17, P.O Box 2888, CH-1211 Genève 1.
HSBC GIF Global Equity Sustainable Healthcare is a sub fund of HSBC Global Investment Funds, a Luxemburg domiciled SICAV. Before subscription, investors should refer to Key Investor Document (KIID) of the fund as well as its complete prospectus. For more detailed information on the risks associated with this fund, investors should refer to the complete prospectus of the fund. The shares of HSBC Global Investment Funds have not been and will not be offered for sale or sold in the United States of America, its territories or possessions and all areas subject to its jurisdiction, or to United States Persons.
Any forecast, projection or target where provided is indicative only and is not guaranteed in any way.
Allocation is as at the date indicated, may not represent current or future allocation and is subject to change without prior notice.
These examples are historical and contains information that is not current and should not be construed as an advice, an offer to sell or solicitation of an offer to purchase or subscribe to any investment.
Swing pricing and Gates: Yes.
“Swing pricing” is a price adjustment mechanism intended to protect the unitholders, or shareholders, of a collective investment undertaking (UCI) against the transaction costs borne by this UCI due to new subscriptions or new buyouts. These transaction costs include, but are not limited to, broker commissions (for equities), the spread between the bid and ask prices (for interest rate products), taxes on financial transactions, fees transactions taken by the depositary, etc.
The fund has a redemption threshold (gate), the level at which the manager of an undertaking for collective investment in transferable securities can stagger the redemption of securities instead of proceeding immediately.
Article 8 SFDR =The product promotes environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices even if this is not its central point, or the central point of the investment process.
More information on our ‘Responsible Investment’ Policy and ‘Implementation Procedures’ can be found on our website. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus.
HSBC Asset Management is the brand name for the asset management business of HSBC Group. The above document has been produced by HSBC Global Asset Management (France) and has been approved for distribution/issue by the following entities:
HSBC Global Asset Management (France) - 421 345 489 RCS Nanterre. Portfolio management company authorised by the French regulatory authority AMF (no. GP99026) with capital of 8.050.320 euros, in Italy, Spain and Sweden through the Milan, Madrid and Stockholm branches of HSBC Global Asset Management (France), regulated respectively by Banca d’Italia and Commissione Nazionale per le Società e la Borsa (Consob) in Italy, the Comisión Nacional del Mercado de Valores (CNMV) in Spain and the Swedish Financial Supervisory Authority (Finansinspektionen) in Sweden. Offices: HSBC Global Asset Management (France)
Immeuble Coeur Défense - 110, esplanade du Général Charles de Gaulle - 92400 Courbevoie - La Défense 4 – France.
HSBC Global Asset Management (Switzerland) AG: Gartenstrasse 26, P.O. Box, CH-8002 Zurich. Paying agent: HSBC Private Bank (Suisse) S.A., Quai des Bergues 9-17, P. O. Box 2888, CH-1211 Geneva 1 In respect of the units distributed in Switzerland, the competent courts shall have exclusive venue at the registered office of the Representative in Switzerland. The official documents as per Art. 13a CISO as well as the (Semi-)Annual Report of the Fund may be obtained free of charge at the office of the Representative in Switzerland.
Non contractual document
Copyright : All rights reserved © HSBC Global Asset Management (France), 2021.